Drugmakers push the FDA to resume inspections after drug approvals delayed, denied

Drugmakers are pushing the FDA to resume inspections halted by the pandemic after the agency has deferred or denied drug approvals because it couldn't inspect manufacturing plants in person, Politico reported March 2.